We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Inefficacy Kills Late-Stage Trial of Revlimid in Prostate Cancer
Inefficacy Kills Late-Stage Trial of Revlimid in Prostate Cancer
December 7, 2011
Celgene is stopping a Phase III trial of blockbuster myeloma drug Revlimid to treat castrate-resistant prostate cancer after the formulation failed to show benefit over placebo.